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Abstract
Hirschsprung disease (HSCR) is a neurocristopathy characterized by absence of intramural ganglion cells along variable
lengths of the gastrointestinal tract. The HSCR phenotype is highly variable with respect to gender, length of aganglionosis,
familiality and the presence of additional anomalies. By molecular genetic analysis, a minimum of 11 neuro-developmental
genes (RET, GDNF, NRTN, SOX10, EDNRB, EDN3, ECE1, ZFHX1B, PHOX2B, KIAA1279, TCF4) are known to harbor rare, high-
penetrance mutations that confer a large risk to the bearer. In addition, two other genes (RET, NRG1) harbor common, low-
penetrance polymorphisms that contribute only partially to risk and can act as genetic modifiers. To broaden this search, we
examined whether a set of 67 proven and candidate HSCR genes harbored additional modifier alleles. In this pilot study, we
utilized a custom-designed array CGH with ,33,000 test probes at an average resolution of ,185 bp to detect gene-sized
or smaller copy number variants (CNVs) within these 67 genes in 18 heterogeneous HSCR patients. Using stringent criteria,
we identified CNVs at three loci (MAPK10, ZFHX1B, SOX2) that are novel, involve regulatory and coding sequences of neuro-
developmental genes, and show association with HSCR in combination with other congenital anomalies. Additional CNVs
are observed under relaxed criteria. Our research suggests a role for CNVs in HSCR and, importantly, emphasizes the role of
variation in regulatory sequences. A much larger study will be necessary both for replication and for identifying the full
spectrum of small CNV effects.
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Introduction
Among newborns, the most frequent cause of a functional
intestinal obstruction is Hirschsprung disease (HSCR: MIM#
142623), or congenital aganglionosis, a neuro- developmental
defect associated with the lack of intramural ganglion cells in the
myenteric and sub-mucosal plexuses along varying segments of the
gastrointestinal tract [1]. The disorder is classified into short-
segment (S-HSCR: aganglionosis up to the upper sigmoid colon),
long-segment (L-HSCR: aganglionosis up to the splenic flexure
and beyond) and total colonic aganglionosis (TCA) forms. HSCR
usually occurs as an isolated trait in ,70% of cases: the remainder
comprises those with a recognized chromosomal abnormality, a
recognized syndrome or additional congenital anomalies [2]. This
birth defect is not uncommon and shows population incidences of
15, 28 and 21 cases per 100,000 live births among Europeans,
Asians and Africans, respectively [1]. The disease has all the
imprints of a multifactorial disorder and shows high heritability
(81%–100%, depending on the sex of the proband and affected
sibling), a large sex-difference (3.9 male: female), a high sibling
recurrence risk (200-fold greater than the population) and non-
Mendelian inheritance in families [1].
Importantly, HSCR displays a highly variable phenotype with
variation in recurrence risk by gender, familiality, segment length
of aganglionosis and associated phenotypes [3]. The reasons for
much of this variation are largely unknown, although gene
discovery has clarified some genotype-phenotype correlations.
Numerous molecular genetic studies have identified rare high-
penetrance mutations in 11 genes (RET, GDNF, NRTN, SOX10,
EDNRB, EDN3, ECE1, ZFHX1B, PHOX2B, KIAA1279, TCF4)i n
HSCR [1,2]. However, cumulatively, these mutations explain only
a minority (,5%) of cases. Additional phenotypic variation is
explained by two common low-penetrance polymorphic variants
at RET [4] and NRG1 [5], but the vast majority (,80%) of HSCR
heritability is still hidden or missing [6].
One possible reason for the hidden heritability in HSCR is the
inadequate study of structural variants, i.e., insertions, deletions,
inversions and translocations, of which copy number variants
(CNVs) are only one part. Three types of studies suggest that such
genomic variants may make an important contribution to HSCR
risk. First, early cytogenetic studies identified trisomy 21 (Down
Syndrome, DS) as a frequent occurrence in HSCR: it is observed
in between 2–10% (average 5%) of cases and is, consequently, 40-
fold more common than in the general population of newborns;
conversely, ,0.8% of individuals with DS have congenital
aganglionosis [7]. Second, large deletions at 10q11–q21, 13q22–
q32 and 2q21–q23 have been identified in HSCR patients with
additional anomalies [2]. Third, a survey of statistically significant
associations between congenital malformations and non-mosaic,
recurrent, single, contiguous autosomal deletions and duplications,
detectable by karyotyping identified 13q22–q32 and 17q21 dele-
tions and 17q21–q23 duplications in HSCR [8,9]. Importantly,
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HSCR: DS-associated HSCR is now known to be partially
mediated through the RET low-penetrance enhancer polymor-
phism [10,11]; the deletions at 10q, 13q and 2q contributed to the
positional identification of RET [12], EDNRB [13] and ZFHX1B
[14], respectively; and, the 17q locus harbors a novel dosage-
sensitive HSCR gene [8,9].
The role of large genomic mutations in HSCR is not in doubt,
but these types of mutations are, nevertheless, rare and invariably
deleterious. Modern genomic technologies now allow a compre-
hensive search for structural variation of all sizes in the human
genome. Indeed, smaller structural variants are common in the
human genome and have been shown to be responsible for many
human traits and diseases [15–17]. These genomic variants are an
important source of phenotypic diversity since they can directly
influence the expression of genes in their vicinity in a dosage-
dependent manner [18] and probably also the timing of their
expression [19]. Consequently, the smaller structural variants can
act as strong genetic modifiers of human disease above and beyond
their role as susceptibility mutations and, we hypothesize, they will
be an integral part of all multifactorial diseases.
Technically, studies of small structural variants, are difficult and
so their roles in disease have been incompletely investigated. In
HSCR, two studies failed to detect any structural variants in the
RET, GDNF, EDN3 and ZFHX1B genes in 208 Spanish [20] and
80 German [21] patients with largely isolated HSCR. Both of
these studies used the MLPA (multiplex ligation-dependent probe
amplification) technique to assess dosage changes in the coding
sequence only to conclude that structural variants are uncommon
in HSCR [20,21]. Consequently, we conducted a broader search
for functional dosage variants (1) using the array CGH
(comparative genomic hybridization) method, (2) scanning both
coding and non-coding (regulatory) sequences, and, (3) screening a
diverse collection of 18 HSCR patients that varied by recognized
risk categories, i.e., gender, familiality, segment length of
aganglionosis and associated anomalies. We also screened a large
collection of 67 known and well-validated candidate HSCR genes
that arose from experimental studies in humans and mice. These
include genes identified by human linkage analysis, human
association studies, large and recurrent genomic deletions in
patients, as well as genes for mouse aganglionosis phenotypes and
transcripts dys-regulated in the gastro-intestinal (GI) tracts of Ret
mouse mutants [22]. Our study revealed three variants, an
intronic 3.5 kb deletion in MAPK10, a recurrent 1.6 kb exonic
duplication in ZFHX1B, and a recurrent 600 bp 59UTR
duplication in SOX2, that are potential modifiers of HSCR.
Interestingly, these modifiers are enriched in those HSCR patients
who also have additional anomalies beyond aganglionosis.
Materials and Methods
Human samples used in the study
We included a diverse collection of patients that differed by the
known categories of risk variation, namely, gender, familiality,
segment length of aganglionosis and associated phenotypes. In
addition, we did not sample any case that was already known to
harbor a structural variant. We sampled 18 Hirschsprung disease
patients of whom 16/2 were male/female, 6/12 were multiplex/
simplex cases, 8/3/4/3 had the aganglionic segment as S-HSCR/
L-HSCR/TCA/unknown, and, 10/8 were isolated/had addition-
al anomalies. The vast majority of our patients, including these 18,
are of European origin given our sites of collection but we do not
have this information on 9 cases since providing information on
race/ethnicity was voluntary. These patients are not a random
collection but chosen to represent all categories in a first set of
experiments. We studied DNA from the proband (where available)
or a sibling with the phenotype of interest. The parental and
available family members’ DNA of subject 150.3 were also
examined for the MAPK10 deletion to determine its segregation
pattern. All patient samples were obtained with written informed
consent approved by the Johns Hopkins University School of
Medicine IRB. For aCGH studies we purchased control DNA
from Promega Corporation (Madison, WI, USA) that included a
mixture of genomic DNA from six unrelated males and six
unrelated females, respectively.
Candidate genes selected for aCGH
We opted to include only well-validated HSCR genes, as
opposed to suspected pathway-based gene selection, to increase
the likelihood of detecting and interpreting structural variants.
Consequently, we selected 67 genes for study that were proven to
have a role in HSCR by the identification of mutations in human
patients (12 genes) or in mouse models of aganglionosis (2 genes),
or shown to have statistically significantly altered gene expression
in comparisons of the GI tract of Ret
+/+ (wild-type) versus Ret
2/2
(null) mice (53 genes). Specifically, the categories and genes
selected were: (1) Genes from human linkage analysis (n=10):
RET, GDNF, SOX10, EDNRB, EDN3, ECE1, ZFHX1B, KIAA1279,
GRB10, NRTN; (2) Genes from human association studies (n=2):
NRG1, SEMA3A; (3) Genes recognized from large recurrent
deletions (n=3): RET, EDNRB, ZFHX1B; (4) Genes recognized
through a mouse aganglionosis phenotype (n=2): PHACTR4, ZIC2;
(5) Genes dys-regulated by mouse Ret mutation (n=53): ELAVL4,
SYT11, MLLT11, TGFB2, DLX1, HOXD4, TMEFF2, ARHGEF3,
TAGLN3, GAP43, SERPINI1, SOX2, CRMP1, UCHL1, PHOX2B,
MAPK10, CARTPT, PCDHA1, DPYSL3, NSG2, VIP, ETV1, STMN2,
ELAVL2, GFRA1, HMX3, EBF3, GNG3, PHOX2A, CADM1, PRPH,
ASCL1, TBX3, MAB21L1, GNG2, SCG3, TUBB3, MAPT, HOXB5,
CDH2, STMN3, SOD1, IL10RB, IFNGR2, SON, CBR1, TTC3,
TFF3, CSTB, PFKL, DCX, FGF13, L1CAM. Detailed information on
these HSCR genes and their probe coverage on the CGH array we
used, as well as the literature citation demonstrating their
candidacy, are provided in Table S1. All gene and locus positions
were with respect to the human genome build hg18.
High-density array CGH (aCGH) design
For aCGH analysis we used the Agilent 4644 K custom-
designed high-density microarray consisting of 45–60 nt (nucleo-
tide) isothermal oligonucleotide probes. Each array consisted of
32,330 test probes and 12,885 control probes (45,215 total probes
per array). The test probes covered the 67 HSCR genes from their
59UTR to their 39UTR with a higher density of tiling probes across
each annotated exon 620 nt. Thus, each gene was represented at
an average resolution of 185 nt but this was ,25 nt and ,240 nt
for coding and non-coding regions, respectively. The control probes
had an average coverage of ,348 kb and provided a genomic
backbone and were of four types: 1,262 Agilent normalization
probes, 30165 Agilent replicate probes, 2,118 Agilent control
probes and 8,000 custom control probes.
For hybridization analysis, test DNAs were digested with AluI
and RsaI followed by labeling the test DNAs with Cy5-dCTP (red
fluorescence) and the sex-matched control DNA with Cy3-dCTP
(green fluorescence), using the Invitrogen BioPrime Array CGH
genomic labeling kit (Invitrogen Corporation, Carlsbad, CA).
Purification of labeling products, array hybridization and washing
were performed according to the manufacturers’ instructions.
The slides were then scanned into image files using an Agilent
CNV Modifiers of Hirschsprung Disease
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image file was achieved using the Agilent Feature extraction
software (v9.5), and text file outputs were imported into an in-
house analysis package for dosage analysis.
Data Analysis and Structural Variant detection
After image analysis, the raw intensities from the red and green
channels were adjusted by subtraction of the background intensity
and preprocessed using a variance stabilizing normalization
procedure. This procedure, called vsn2, provides straightforward
methods for preprocessing two-channel arrays by calibrating the
dependency between the mean and variance of the raw intensity
measurements while accounting for both the foreground and
background intensities, within a model framework [23]. This
analysis was performed for each array analyzed. To avoid the
influence of outliers in the raw intensities, we trimmed the largest
10% of the residuals when estimating the parameters in vsn2.
Consequently, we performed the locally weighted linear regression
using the lowess function in R [24], for the red and green channels
separately to smooth out the systematic effect caused by the GC-
content variation in the probe sequences. These final residuals from
the lowess regression were used for further analysis. To control for
batch effects during experimental array processing, we utilized the
1,262 normalization probes from Agilent and our 8,000 control
probes. We performed quantile normalization on each array so that
the red and green intensities of the control probes had the same
mean absolute difference (MAD) and the log2 ratio of the red over
green intensities had their median centered at zero. The between
array normalization procedure was performed using the marray R
package available through www.bioconductor.org.
The post-normalization relative intensity data log2R, where
R= red/green intensity, were plotted against their genomic
location and outliers were smoothed using a sliding window of five
probes. For a given smoothed region, we calculated its median (m)
from the local observations. We also trimmed the most extreme
2.5% of observations to calculate the standard deviation ^ s s ðÞfor
the entire data set. For a given smoothed region, an outlier was
determined and smoothed if the difference between maximum or
minimum intensity and its closest neighboring probe exceeded 4^ s s:
we replaced these observations by m + 2^ s s. After smoothing of
outliers, we used the circular binary segmentation procedure
(CBS) [25] to detect copy number with a Type-I error (a) of 0.01.
For the segmented region reported by CBS, we examined the
intensities across $10 probes and used a stringent criterion to call a
duplication if log2R$ log2(1.5) = +0.58, a deletion if log2R #
log2(0.5) = 21, and a normal diploid dosage if 21, log2R
,0.58. Although the stringent criterion can reduce false positive
CNV identification it can also increase the false negative rate.
Thus, we also analyzed our results using the following relaxed
criterion: call a duplication if log2R$ log2(1.5) = +0.40, a deletion
if log2R # log2(0.5) = 20.80, and a normal diploid dosage if
20.80, log2R ,0.40. Finally, we also used the commercial
proprietary software provided by Agilent (Genomic Workbench,
Standard Edition, V 5.0.14) to call CNVs. Nevertheless, the actual
duplication and deletion calls utilized the identical stringent and
relaxed criteria indicated earlier. The array data have been
presented in accordance with MIAME guidelines and deposited
in NCBI’s Gene Expression Omnibus [26]. All data are accessible
through the GEO Series accession number GSE29051 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29051).
PCR assays
For further analysis of aCGH-inferred CNVs, we initially used
the oligonucleotide intensity data to approximate the genomic
breakpoint positions for each variant. For MAPK10 deletion
analysis, based on these coordinates, we designed inward-facing
primers to amplify the deletion allele (forward primer 59 to 39:
TTGACAAGCTCCCACCAACATAAT; reverse primer 59 to 39:
ACCAGCAACCATGATGAAGTGAAT). Standard PCR was
then conducted with Thermo-Start PCR Master Mix (AB-0938/
15/DC/B). A 50 ml PCR reaction was performed with 1 mMo f
each primer, 25 mlo f2 6Thermo-Start PCR Master Mix and
50 ng of template DNA. The PCR conditions were as follows:
95uC for 15 min, 35 cycles of 95uC for 20 s, 60uC for 30 s and
72uC for 1 min, followed by 72uC for 5 min.
Results
We performed analysis on 18 patient samples using 28 arrays,
involving replicate samples, to assess the reliability of results.
Specifically, 11 samples (#’s 47, 150, 242, 252, 346, 348, 359, 370,
372, 384, 423) were studied once, 4 (#’s 300, 354, 355, 408) were
examined twice while 3 (#’s 63, 122, 413) were studied in
triplicate. First, in order to investigate the consistency of the
intensity readings between the technical replicates, we calculated
the Pearson correlation of the raw intensities between replicates
(mean r=0.72 across 13 comparisons) and between randomly
selected samples (mean r=0.42 across 13 comparisons), a
difference that was statistically significant (P=0.004). Second, we
investigated whether this difference would be enhanced after
statistical pre-processing of arrays. After normalization, the mean
correlation was 0.69 between replicates and 0.32 between
randomly selected samples, a difference that was more enhanced
(P,0.0001). Since the results between technical replicates were
similar, we averaged the log2R between technical replicates for
CNV segmentation analysis.
We next investigated the role of stringent versus relaxed criteria
on CNV assessment. Consequently, we identified all CNVs
meeting our criteria using our method and Agilent’s method for
identifying dosage variants. First, none of our analyses identified a
single large deletion or duplication involving an entire or the
majority of any of the 67 genes we investigated. Consequently, we
presume that these are rare in the HSCR population and so we
need to screen larger numbers of cases. Our method, however,
identified 3 small dosage variants, namely, a deletion in MAPK10,
a duplication involving ZFHX1B, and a duplication involving
SOX2 using the stringent criterion. Under the relaxed criterion, we
identified 2 additional deletions of PHOX2B and SEMA3A, each
occurring in two patients. Using the Agilent software, we identified
5 additional duplications (GDNF: 2 cases, GNG2: 1 case, TTC3:2
cases, GAP43: 1 case, NRG1: 1 case) but failed to see the prior
SEMA3A deletion. Thus, the Agilent methods detected almost
twice as many CNVs (9) as our method (5), while there was about
equal concordance (60%) between the stringent vs. relaxed
criterion on both methods. Finally, for the three CNVs common
to all methods, the concordance within either method and across
stringency was 76% while that between the methods within
stringency was 46% (relaxed) to 67% (stringent). Consequently, we
used our method and the stringent criterion to identify biologically
significant deletions and duplications.
For further analysis we restricted attention to the three common
variants in 18 heterogeneous HSCR patients (Table 1): deletion in
intron 11 of MAPK10, duplication involving exon 2 of ZFHX1B,
and duplication in the 59UTR of SOX2. The MAPK10 deletion, on
chromosome 4 at location 87,195,268 (hg18), was a 3.5 kb lesion
detected using 13 probes in a single sample (Figure 1A). The
ZFHX1B duplications, on chromosome 2 and starting at locations
144,989,981–144,990,319 (hg18), were detected in 4 patients using
CNV Modifiers of Hirschsprung Disease
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(Figure 2A). Finally, the SOX2 duplications, on chromosome 3,
starting at locations 182,912,064–182,912,387 (hg18), were
detected in 5 patients using between 12–19 probes and were
between 330–800 bp in length (Figure 3A). The most parsimoni-
ous explanation of the ZFHX1B and SOX2 duplications detected in
multiple individuals is that it is the same genetic mutation in each
gene, with the differences arising from random experimental noise
across arrays. The detection of the same CNV in different array
experiments and the demonstration of segregation of the solitary
MAPK10 deletion (see below) suggests that these structural variants
are biologically meaningful.
The main question is whether these three CNVs contribute to
the HSCR phenotype. Family studies are one way to assess the
biological relevance of a rare variant, as with the MAPK10 variant.
The 3.5 kb MAPK10 deletion, detected in subject 150.3, was
confirmed by a standard PCR assay which amplified only the
deletion allele of 1.1 kb; the expected product size of the wild type
allele is 4,608 bp but was not observed because the experiment
was optimized for smaller fragment only. Segregation analysis of
this deletion in related family members showed that the proband
inherited this deletion from his unaffected father (the mother is
unaffected as well), shares it with a HSCR-affected sister and
transmitted it to only one of his three HSCR-affected children
(Figure 1B). Under pure autosomal dominant inheritance, it would
be unlikely that the MAPK10 deletion would be a necessary and
sufficient explanation of HSCR in this family. This family,
however, shows complex inheritance because all five affected
family members harbor a RET S649S mutation, which although
synonymous we have previously demonstrated to lead to aberrant
exon 11 splicing and shows strong linkage to a RET modifier locus
on human chromosome 9q31 [27]. Consequently, we hypothesize
that the MAPK10 deletion is another genetic component to the
multifactorial HSCR risk in this family since this mitogen-
activated protein kinase 10 gene is highly expressed in the
myenteric layer of the intestine and is the most significantly down-
regulated gene in the mouse Ret
2/2 GI tract [22]. Biochemically,
the protein acts as an integration point for multiple biochemical
signals, and is involved in a wide variety of cellular processes such
as proliferation, differentiation, transcription regulation and
development. On the other hand, a number of small CNVs
within this intron 11 are observed in multiple unrelated healthy
controls or Hapmap samples (at frequencies between 2% to 6.6%)
[28–30] in the Database of Genomic Variants (DGV) (Figure 1C).
Although, this would seem to argue against a functional role for
the deletion we observed the frequency is small, the allele may only
be a susceptibility variant, and, the deletion, along with 5 deletions
and 1 duplication found in the DGV, does involve a DNase I
hypersensitive site cluster, a transcription factor binding site cluster
and an activating H3K4me1 histone mark (Figure1C). These sites
overlap significantly and, therefore, could represent the same
binding site for MAPK10 activation. Although yet unproven, these
results suggest that haplo-insufficiency for this regulatory site may
be a modifier for HSCR per se or the other associated traits in this
patient and his family (Table 2).
The recurrent novel duplications of ZFHX1B we identified in
four patients (Figure 2A) is likely biologically meaningful as well.
The aCGH data are internally consistent across replicates to show
a small 1.42–1.99 kb duplication involving exon 2 and including
part of intron1 (Figure 2B). Nevertheless, two pairs of inward and
two pairs of outward primers failed to verify the structural variant
(data not shown), although a TaqMan copy number assay (# 9123
in Figure 2B) detected one copy for subject 370.3 and two copies
for the other three subjects. These results are not unexpected for a
duplication where the presence of additional similar sequence can
lead to multiple priming sites beyond the ones intended.
Annotations of this region show evolutionary conservation of
exon 2 to lizard, Xenopus tropicalis and teleost fish (Figure 2B).
Functional annotations show multiple DNase I hypersensitive sites,
transcription factor binding sites and promoter H3K4me3 histone
marks (Figure 2B). These sites overlap significantly with the coding
exon 2 and immediately downstream sequences and, therefore,
could represent either duplication or disruption of a wild type
regulatory element for ZFHX1B. Haplo-insufficiency of ZFHX1B
is the cause of Mowat-Wilson syndrome and we are unaware what
a duplication phenotype might be. However, ZFHX1B is such a
critical regulator of epithelial- mesenchymal transitions (EMT)
throughout neural crest development that it is very likely a
modifier of HSCR per se or the other associated traits with which it
is observed (Table 2).
We identified a second novel recurrent duplication in SOX2 in
five patients (Figure 3A) that is similarly biologically meaningful.
The aCGH data are internally consistent across replicates to show
a small 600 bp duplication likely involving most of the 59UTR
(Figure 3B). Nevertheless, a TaqMan Copy Number Assay
(# 9669 in Figure 3B) failed to detect the variant, as before.
Table 1. Copy number variants (CNVs) detected by array comparative genomic hybridization (aCGH) in 8 Hirschsprung disease
patients.
Subject Gene
Copy number
change
Location
(hg18) Size (kb) # probes Mean log2R
252.3 ZFHX1B Gain Chr2: 144,989,981 1.99 10 0.65
370.3 ZFHX1B Gain Chr2: 144,989,981 1.76 10 0.76
63.3 ZFHX1B Gain Chr2: 144,990,319 1.42 10 0.95
372.3 ZFHX1B Gain Chr2: 144,990,319 1.42 11 0.86
242.4 SOX2 Gain Chr3: 182,912,064 0.65 18 1.02
252.3 SOX2 Gain Chr3: 182,912,064 0.65 19 1.84
300.3 SOX2 Gain Chr3: 182,912,064 0.65 18 1.73
372.3 SOX2 Gain Chr3: 182,912,387 0.33 16 0.96
423.3 SOX2 Gain Chr3: 182,912,387 0.80 12 0.73
150.3 MAPK10 Loss Chr4: 87,195,268 3.50 13 21.29
doi:10.1371/journal.pone.0021219.t001
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21219Figure 1. MAPK10 dosage variant in Hirschsprung disease. We show the MAPK10 deletion profile from aCGH analysis (A), its segregation
pattern within a family (B), and, the corresponding genomic locus in the UCSC Genome Browser (hg18) (C). The grey rectangle in (C) delineates the
CNV region in subject 150.3; RefSeq gene boundaries are shown in light blue; the Database of Genomic Variants entries are shown with red indicating
gain and blue indicating loss of material relative to the reference sequence.
doi:10.1371/journal.pone.0021219.g001
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59UTR to lizard, Xenopus tropicalis and chicken. Functional
annotations show multiple DNase I hypersensitive sites, transcrip-
tion factor binding sites and promoted H3K4me3 histone marks
(Figure 3B). These sites overlap significantly and suggest a critical
regulatory element for SOX2 that is disrupted in HSCR and could
act as a modifier (Table 2).
Our results, summarized in Table 2, demonstrate a striking
feature: the incidence of structural variants in the three genes
discovered is higher in the HSCR families with additional
anomalies and, indeed, they co-occur in some families. This
association is highly significant since the 10 isolated HSCR
patients have only one variant but the 8 HSCR cases with
additional anomalies have 7 variants (P=0.0029). If we included
all other CNVs detected, specifically the 9 variants detected by
Agilent analysis using the relaxed criterion, this association is still
highly significant, with the 10 isolated HSCR patients having only
two variants but the 8 HSCR cases with additional anomalies
having 7 variants (P=0.015). In other words, the increased
frequency of dosage variants is enhanced in the HSCR cases with
additional anomalies (except for family #348) and in only one
family with isolated HSCR (family #370). Interestingly, the
families with multiple anomalies also show a greater frequency of
RET coding or splicing mutations and these families tend to have
more severe (L-HSCR, TCA) forms of HSCR and more RET
enhancer variant heterozygotes, as previously noted in trisomy 21-
HSCR cases [11]. These data suggests two classes of HSCR
patients. The families which have anomalies in addition to HSCR,
none of which have recognized syndromes (such as Down, Mowat-
Wilson, Shah-Waardenburg, etc.), have a propensity to be familial
Figure 2. ZFHX1B dosage variant in Hirschsprung disease. We show the ZFHX1B duplication profile from aCGH analysis (A), and, the
corresponding genomic locus in the UCSC Genome Browser (hg18) (B). Functional annotation of this region shows multiple DNase I hypersensitive
sites, transcription factor binding sites and promoted H3K4me3 histone marks. Evolutionary conservation across species is also shown.
doi:10.1371/journal.pone.0021219.g002
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MAPK10, ZFHX1B, and SOX2. On the other hand, most patients
with isolated HSCR are neither familial nor have RET coding or
structural variant mutations. As we have shown elsewhere, and in
Table 2, these latter patients are more likely to harbor regulatory
polymorphisms such as in the RET intron 1 enhancer [3,4] or
intron 1 of NRG1 [5].
Discussion
HSCR is a multifactorial disorder where multiple rare and
common mutations exist within each patient. With the exception
of the major gene RET, no other mutation is yet known to be
necessary for this neuro-developmental birth defect [1–3].
Consequently, any single HSCR gene is expected to be mutant
in only a subset of patients implying that the number of genes
involved and their mutational types are numerous. In this study,
we conducted an investigation into the frequency of small
structural variants in HSCR since they are numerous in the
human genome [15–17] and likely to exist in all genes, including
in HSCR genes. Studies by others have assessed the role of these
small CNVs in 288 European patients, but in only 4 HSCR genes
[20,21]. We chose instead to search for such dosage mutations in a
more extensive set of 67 HSCR genes, all involved in enteric
nervous system (ENS) development, in 18 diverse HSCR patients.
We identified no changes that were full gene deletions or
duplications although we had the ability to detect such mutations
and specifically included cases with multiple anomalies where this
Figure 3. SOX2 dosage variant in Hirschsprung disease. We show the SOX2 duplication profile from aCGH analysis (A), and, the corresponding
genomic locus in the UCSC Genome Browser (hg18) (B). Functional annotation of this region shows multiple DNase I hypersensitive sites,
transcription factor binding sites and promoted H3K4me3 histone marks. Evolutionary conservation across species is also shown.
doi:10.1371/journal.pone.0021219.g003
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we conclude that the frequency of whole gene dosage mutations
are rare in HSCR. However, three variants in MAPK10, ZFHX1B,
and SOX2, that are all likely regulatory, but of unknown specific
function, were identified in 8 out of 18 patients (44%) and
appeared to be modifiers of HSCR. These three genes point to
pathways of critical importance to ENS development, supporting
that their disruption may lead to HSCR.
MAPK10 encodes a neuronal-specific form of c-Jun N-terminal
kinases (JNKs) and is highly expressed in the mouse myenteric
segment of the intestine [22]. In the mouse, Mapk10 activation is
associated with responses to inflammation and cellular stresses, but
also with cytoskeletal changes associated with neuronal growth.
Mapk10 binds and phosphorylates Stmn2 (Stathmin like-2)
regulating its microtubule-destabilizing activity [22]. Since Ret,
Mapk10, and Stmn2 are all expressed in the ENS, we hypothesize
that these molecules function together to link extracellular signals
to the rearrangement of the neuronal cytoskeleton required for
axonal outgrowth [31]. As explained earlier, the deletion variant is
most likely a regulatory mutation that deletes a dosage-dependent
binding site for MAPK10 activation. This is a rare polymorphism
in humans (2% to 6.6%) [28–30] and probably has no effect on its
own but could lead to HSCR in the context of a RET splicing
mutation (S649S) that this patient also harbors.
A critical step in neural crest cell genesis is the developmental
transition of neuro-epithelial cells to a mesenschymal fate (EMT),
a transition strongly regulated by two related proteins ZEB1 and
ZEB2 (the protein encoded by ZFHX1B) [32,33]. These proteins
act so early in neural crest development that it is not surprising
that de novo heterozygous deletions of ZFHX1B lead to HSCR-
related Mowat-Wilson syndrome. The protein encoded by this
gene is a member of the Zfh1 family of 2-handed zinc finger/
homeodomain proteins. It is located in the nucleus and functions
as a DNA-binding transcriptional repressor that interacts with
activated SMADs. It is difficult to predict what duplication of exon
2 might do, but duplications usually lead to milder phenotypes.
Since all four patients with ZFHX1B duplications also carry a RET
mutation we suspect that these duplications act as a HSCR
modifier. A broader search for ZFHX1B regulatory mutations in
HSCR would clarify this relationship with RET signaling.
SOX2 is an intronless gene that encodes a member of the SRY-
related HMG-box family of transcription factors involved in the
regulation of embryonic development and in the determination of
cell fate. The protein is strongly implicated in the determination of
neurogenesis and also regulates gene expression in the stomach; it
is expressed in the mouse ENS in a pattern indistinguishable from
that of the established ENS transcription factors Mash1, Phox2a,
Phox2b and Sox10 [22]. In fact, SOX1-3 keep neural cells
undifferentiated by counteracting the activity of proneural proteins
and the generation of neurons from stem cells critically depends on
the inhibition of SOX1-3 expression [34,35]. Consequently, we
hypothesize that duplications involving the 59UTR of this gene
might lead to increased expression of SOX2 and affect the process
of neurogenesis by maintaining proliferation and/or the mainte-
nance of neural stem cells. This can lead to modification of
ganglionosis, and thus HSCR. Interestingly, 3 of 4 SOX2
duplication carriers also carried RET mutations suggesting another
basis for interaction.
Table 2. Clinical features, RET gene sequence, enhancer genotype and dosage mutations in aCGH analysis of 18 Hirschsprung
disease patients.
Subject Gender
HSCR
type
Segment
length
Additional
anomalies RET mutation
RET enhancer
variant CNV
408.3 Male Isolated S-HSCR none NA NA -
346.3 Male Isolated L-HSCR none none CT -
370.3 Male Isolated S-HSCR none none CC ZFHX1B duplication
354.3 Male Isolated S-HSCR none none CT -
355.3 Male Isolated L-HSCR none none TT -
359.3 Male Isolated S-HSCR none none CC -
413.3 Male Isolated S-HSCR none NA NA -
384.3 Male Isolated S-HSCR none none TT -
122.7 Male Isolated TCA none none TT -
47.3 Male Isolated S-HSCR none none TT -
348.3 Male Additional anomaly L-HSCR Duane anomaly none TT -
252.3 * Male Additional anomaly TCA UT reflux, Meckel’s diverticulum L404P CT ZFHX1B duplication;
SOX2 duplication
300.3 Female Additional anomaly unknown GI malrotation none CT SOX2 duplication
372.3 * Male Additional anomaly TCA Neuronal intestinal dysplasia S307L CT ZFHX1B duplication;
SOX2 duplication
242.4 * Female Additional anomaly TCA Ptosis F998L CT SOX2 duplication
423.3 * Male Additional anomaly S-HSCR Ptosis NA NA SOX2 duplication
63.3 * Male Additional anomaly unknown Strabismus I464V TT ZFHX1B duplication
150.3 * Male Additional anomaly unknown Strabismus S649S CC MAPK10 deletion
Abbreviations: S-HSCR, short segment HSCR; L-HSCR, long segment HSCR; TCA, total colonic aganglionosis; NA = not available.
Patients from multiplex families are indicated by *. RET enhancer variant refers to rs2435357 in intron 1 of RET, with ancestral allele.
C and derived mutation allele T.
doi:10.1371/journal.pone.0021219.t002
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importantly, emphasizes the role of variation in regulatory
sequences. Most studies of structural variation in human disease,
based on array CGH, focus on large lesions of 300 kb or greater.
This has become a powerful tool for the molecular elucidation and
diagnosis of disorders resulting from genomic copy number
variation. However, the vast majority of intragenic deletions or
duplications, that is smaller than a gene, have remained beyond
the detection limit of most clinical aCGH analyses. The primary
reasons for this are the increased numbers of probes needed for
genomic resolution, and the consequent higher cost, the difficulty
of interpreting non-coding CNVs, and the enhanced detection of
benign CNVs that can confound clinical interpretation. However,
the increasing biological annotation of the non-coding segments of
the human genome [36] is improving the interpretation of non-
coding CNVs [37–39].
This study raises two major questions in human medical
genetics with respect to causation, namely, (1) which genes should
be considered primary (main) and which modifiers, and, (2) which
patients are most likely to harbor multiple gene or genomic
mutations? The accepted definition of a modifier gene (allele) is
one that is not necessary for disease causation (principal gene) but
one that alter phenotype penetrance and expressivity. Conse-
quently, the role of modifiers in the inheritance of single gene
disorders is clear, as first suggested by Haldane [40]. For complex
multifactorial disorders, such as HSCR, this definition can be
extended to the multiple principal genes that impart risk by
coordinate action and the multiple modifier genes that modulate
their response. In this case, since none of the principal genes cause
disease by themselves alone they are individually susceptibility
genes. In reality, no gene can be precisely classified as principal,
modifier or susceptibility since a gene may impart different effects
and have different roles depending on the mutation it harbors. In
HSCR, the 11 neuro-development genes with confirmed muta-
tions are all susceptibility genes since they affect disease risk but
not with complete penetrance suggesting the action of other genes.
However, RET should be considered principal since nearly all
HSCR patients have at least one loss-of-function RET mutation.
In this sense, MAPK10, ZFHX1B, and SOX2 CNVs co-occur with
RET mutations and given their biology is postulated to further
antagonize RET function and are, thus, modifiers. But, these genes
are not universal modifiers since they are rare in patients without
loss-of-function mutations in RET. HSCR in this latter group of
patients probably occur by different, as yet, unknown mechanisms.
These arguments also suggest that the search for modifiers is better
restricted to patients with severe mutations and additional
anomalies.
This study is the first systematic investigation of gene-sized or
smaller structural variants in a large number of HSCR genes in a
cohort of isolated and additional anomalies HSCR patients using
aCGH analysis. Our experiments show the value of documenting
these small structural variants which likely act as modifiers of
additional anomalies in HSCR and begin to explain the
multifactorial inheritance of this common ENS developmental
defect. There has been great attention provided to large genomic
lesions that demonstrate, like other human mutations, less-than-
complete penetrance or the requirement of multiple hits to induce
a phenotype [15,41]. The results in this paper suggest that the
same phenomenon likely acts, to a greater extent, with intragenic
dosage mutations. These observations beg the question: what is a
susceptibility allele and what is a modifier? In this study we have
referred to these dosage alleles as modifiers of HSCR since RET is
necessary for onset of HSCR [3]. We believe that future
investigations using exon-based whole genome arrays can identify
the full spectrum of such small CNV effects in HSCR.
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